clinical trial · NCT07168902
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
GlaucomaBL1107 Low doseBL1107 High doseTimolol maleate 0.5%
brief summary
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension
started
Oct 24, 2025
primary completion
May 1, 2026
completion
May 1, 2026
last updated
Mar 31, 2026
detailed description
This study will evaluate the safety and efficacy of BL1107 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This is a randomized, double-masked, parallel comparison to evaluate two concentrations of BL1107 in both eyes compared with timolol 0.5% for 28 days.
official title
A Phase 2 Evaluation of the Safety, Ocular Tolerability, and Efficacy of Topical Ophthalmic BL1107 Versus Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol